ArticleCNS neuroscience & therapeutics2026
Multidimensional Assessment of Neurological Adverse Reactions Related to PD-1 Inhibitors: A Real-World Pharmacovigilance Study.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPD-1 inhibitors have revolutionized cancer immunotherapy but present significant neurological safety concerns. While clinical trials have documented neurological adverse events (nAEs), a comprehensive understanding of their patterns and risk factors remains limited. This study systematically analyzed a decade of FAERS data to investigate PD-1 inhibitor-associated neurotoxicities.
methodsUsing FAERS data (2014-2024), we conducted disproportionality analyses (ROR, IC, PRR) to assess PD-1 inhibitor-nAE associations. Risk factors were evaluated using logistic regression; timing analyses used log-rank and Mann-Whitney U tests, while group comparisons used Chi-square tests.
resultsAmong 115,000 PD-1 inhibitor-associated adverse events, 7968 (6.93%) involved nAEs, showing an increasing trend from 4.96% (Q4 2014) to 7.67% (Q1-Q2 2024). PD-1 inhibitors showed significant nAE signals (ROR: 1.21, 95% CI: 1.18-1.23), with cemiplimab showing the strongest association (ROR: 1.38, 95% CI: 1.18-1.62). The most common nAEs were dizziness (N = 942, 10.3%), encephalitis (N = 435, 4.8%), and cerebrovascular accident (N = 451, 4.9%). Risk factors included age > 65 years (OR: 1.10), female sex (OR: 1.04), skin cancer (OR: 1.36), and nervous system cancers (OR: 1.44). The median onset time was 34 days (IQR: 12-104), with 63.8% occurring within 2 months and 59% resulting in severe outcomes.
conclusionThis study reveals a spectrum of PD-1 inhibitor-related neurological toxicities, mainly involving central nervous system dysfunction, providing important insights into risk patterns and timing characteristics. These findings support improved clinical monitoring practices and inform the development of personalized patient care strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.